93 related articles for article (PubMed ID: 33638323)
61. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
62. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study.
Endo Y; Kitago M; Aiura K; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Nakano Y; Itano O; Fukada J; Masugi Y; Kitagawa Y
World J Surg Oncol; 2019 Aug; 17(1):145. PubMed ID: 31420046
[TBL] [Abstract][Full Text] [Related]
63. Clinicopathologic features and treatment strategies for patients with pancreatic adenocarcinoma and ovarian metastases.
Falchook GS; Wolff RA; Varadhachary GR
Gynecol Oncol; 2008 Mar; 108(3):515-9. PubMed ID: 18164378
[TBL] [Abstract][Full Text] [Related]
64. Impact of Race, Insurance Status, and Primary Language on Presentation, Treatment, and Outcomes of Patients with Pancreatic Adenocarcinoma at a Safety-Net Hospital.
Sridhar P; Misir P; Kwak H; deGeus SW; Drake FT; Cassidy MR; McAneny DA; Tseng JF; Sachs TE
J Am Coll Surg; 2019 Oct; 229(4):389-396. PubMed ID: 31212101
[TBL] [Abstract][Full Text] [Related]
65. Treatment patterns and survival in patients with early-onset pancreatic cancer.
Saadat LV; Chou JF; Gonen M; Soares KC; Kingham TP; Varghese AM; Jarnagin WR; D'Angelica MI; Drebin JA; O'Reilly EM; Wei AC
Cancer; 2021 Oct; 127(19):3566-3578. PubMed ID: 34228820
[TBL] [Abstract][Full Text] [Related]
66. An analysis of time to treatment in patients with pancreatic adenocarcinoma.
Sugumar K; Gendi S; Quereshy HA; Gupta S; Hue JJ; Rothermel LD; Ocuin LM; Ammori JB; Hardacre JM; Winter JM
Surgery; 2023 Jul; 174(1):83-90. PubMed ID: 37105784
[TBL] [Abstract][Full Text] [Related]
67. Clinical and genomic characterisation of early-onset pancreatic cancer.
Castet F; Fabregat-Franco C; Castillo G; Navarro V; Sierra A; Acosta DA; López-Valbuena D; Dienstmann R; Tabernero J; Vivancos A; Tian TV; Macarulla T
Eur J Cancer; 2023 Nov; 194():113338. PubMed ID: 37793216
[TBL] [Abstract][Full Text] [Related]
68. Clinical characteristics, treatment patterns and survival outcomes of early-onset pancreatic adenocarcinoma: a population-based study.
Ren S; Sadula A; Ye C; Chen Q; Yuan M; Meng M; Lei J; Li G; Yuan C
Am J Transl Res; 2023; 15(1):407-421. PubMed ID: 36777821
[TBL] [Abstract][Full Text] [Related]
69. Early onset pancreatic cancer: evidence of a major role for smoking and genetic factors.
Raimondi S; Maisonneuve P; Löhr JM; Lowenfels AB
Cancer Epidemiol Biomarkers Prev; 2007 Sep; 16(9):1894-7. PubMed ID: 17855711
[TBL] [Abstract][Full Text] [Related]
70. Early onset pancreatic cancer: a controlled trial.
Tingstedt B; Weitkämper C; Andersson R
Ann Gastroenterol; 2011; 24(3):206-212. PubMed ID: 24713777
[TBL] [Abstract][Full Text] [Related]
71. Trends in the Incidence and Treatment of Early-Onset Pancreatic Cancer.
LaPelusa M; Shen C; Arhin ND; Cardin D; Tan M; Idrees K; Geevarghese S; Chakravarthy B; Berlin J; Eng C
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053447
[TBL] [Abstract][Full Text] [Related]
72. Pancreatic cancer in young adults - an evolving entity?
Li Y; Zhang X
Am J Cancer Res; 2023; 13(7):2763-2772. PubMed ID: 37559978
[TBL] [Abstract][Full Text] [Related]
73. Modifiable and Non-Modifiable Risk Factors for the Development of Non-Hereditary Pancreatic Cancer.
Olakowski M; Bułdak Ł
Medicina (Kaunas); 2022 Jul; 58(8):. PubMed ID: 35893093
[TBL] [Abstract][Full Text] [Related]
74. Predictors of Survival among Early Onset Pancreatic Adenocarcinoma Patients A Tertiary Care Center Experience.
Alkashash AM; Elsebaie MA; Bikhet MH; Morsi M; Paluri RK
Chirurgia (Bucur); 2021; 116(1):24-33. PubMed ID: 33638323
[TBL] [Abstract][Full Text] [Related]
75. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
76. Value of lymph node positivity in treatment planning for early stage pancreatic cancer.
Tran Cao HS; Zhang Q; Sada YH; Silberfein EJ; Hsu C; Van Buren G; Chai C; Katz MHG; Fisher WE; Massarweh NN
Surgery; 2017 Sep; 162(3):557-567. PubMed ID: 28666686
[TBL] [Abstract][Full Text] [Related]
77. A comparative analysis of survival outcomes between pancreatectomy and chemotherapy for elderly patients with adenocarcinoma of the pancreas.
Marmor S; Burke EE; Virnig BA; Jensen EH; Tuttle TM
Cancer; 2016 Nov; 122(21):3378-3385. PubMed ID: 27419382
[TBL] [Abstract][Full Text] [Related]
78. Early-onset pancreatic cancer: A national cancer registry study from the Czech Republic and review of the literature.
Whitley A; Kocián P; Nikov A; Krejčí D; Pehalová L; Blaha M; Dušek L; Gürlich R
J Hepatobiliary Pancreat Sci; 2023 Dec; 30(12):1324-1333. PubMed ID: 37750364
[TBL] [Abstract][Full Text] [Related]
79. Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival.
Ulanja MB; Moody AE; Beutler BD; Antwi-Amoabeng D; Rahman GA; Alese OB
Oncotarget; 2022; 13():828-841. PubMed ID: 35720978
[TBL] [Abstract][Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
